Ashling Wahner | Authors


Neoadjuvant Adagrasib With or Without Nivolumab May Better pCR Rates in NSCLC

August 06, 2022

The phase 2 Neo-KAN study revealed neoadjuvant adagrasib alone or in combination with nivolumab may improve pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer.

ADC/ICI Combo Effective in BCG-Unresponsive NMIBC

July 28, 2022

Results from a phase 3 study of pembrolizumab and nadofaragene firadenovec in patients with BCG-unresponsive non–muscle invasive bladder cancer suggests that immune checkpoint inhibitors have synergy with antibody drug conjugates.